Everyone is watching the GLP-1 race, but one of the most interesting compounds in obesity research is not a GLP-1 at all. Cagrilintide works through a different hormone entirely — amylin — and its real significance is what happens when you combine it with semaglutide. If you have seen the name “CagriSema” and wondered where it comes from, cagrilintide is the answer.
What Cagrilintide Is
Cagrilintide is a long-acting amylin analog developed for obesity. Amylin is a natural hormone co-secreted with insulin from the pancreas, and its job is to promote fullness — it slows gastric emptying and signals satiety to the brain. Cagrilintide is a synthetic, once-weekly version engineered to do this in a sustained way. So where GLP-1 drugs mimic one satiety hormone, cagrilintide mimics a different one, which is exactly why it is so interesting.
How It Works — and Why It Is Different
The key is that amylin and GLP-1 are separate pathways that both reduce appetite. GLP-1 agonists like semaglutide work on the GLP-1 receptor; cagrilintide works on amylin receptors. Both reduce food intake and slow digestion, but through distinct signaling. That distinction matters because combining two complementary satiety mechanisms can, in principle, produce more weight loss than either alone — the same logic that makes multi-receptor agonists like retatrutide so potent, but achieved by pairing two drugs instead of one triple-action molecule.
Amylin-based therapy is not entirely new — an earlier amylin analog (pramlintide) has been used in diabetes — but cagrilintide is the long-acting version built for the modern obesity era.
Cagrilintide is not a GLP-1 drug. It mimics amylin, a different satiety hormone — which is why pairing it with semaglutide hits appetite through two doors at once.Why cagrilintide matters
The CagriSema Combination
Cagrilintide’s headline role is as half of CagriSema — the combination of cagrilintide and semaglutide. The idea is elegant: take the most established GLP-1 drug and add an amylin analog that attacks appetite through a separate pathway, and you get additive, possibly synergistic weight loss. In the REDEFINE trial program, CagriSema produced weight loss in the low-20s percent range, placing it among the most effective obesity therapies studied — competitive with the top tier of single-molecule agents. We compare it directly in CagriSema vs retatrutide and CagriSema vs tirzepatide.
On its own, cagrilintide has also shown meaningful weight loss in earlier research — in the roughly 10% range in phase 2 — confirming that the amylin pathway is a real, independent lever and not just a helper. But it is the combination that put cagrilintide on the map.
Results and Status
Here is the honest standing. Cagrilintide is investigational — neither it nor CagriSema is a long-established approved product, and the data comes from clinical trials rather than years of real-world use. The trial results are genuinely strong, especially for the combination, but the long-term safety and effectiveness picture is still being completed. As with every compound in this space, what is in the vial matters enormously, which is why third-party testing is non-negotiable for research material. The full landscape is mapped in our GLP-1 weight-loss drugs guide.
TrueLabs carries cagrilintide as a Canadian-sourced, third-party-tested research peptide with a published certificate of analysis.
FAQ
Tap a question to reveal the answer.
What is cagrilintide?
Cagrilintide is a long-acting amylin analog developed for obesity. Amylin is a natural hormone co-secreted with insulin that promotes fullness and slows gastric emptying, and cagrilintide is a synthetic, once-weekly version engineered to sustain that effect. It is best known as half of the CagriSema combination with semaglutide.
How is cagrilintide different from semaglutide?
They work on different hormones. Semaglutide is a GLP-1 receptor agonist, while cagrilintide mimics amylin, a separate satiety hormone acting through its own receptors. Both reduce appetite and slow digestion, but via distinct pathways, which is exactly why combining them can produce additive weight loss.
What is CagriSema?
CagriSema is the combination of cagrilintide and semaglutide into one therapy. It pairs an amylin analog with a GLP-1 agonist so appetite is targeted through two separate pathways at once. In the REDEFINE trials it produced weight loss in the low-20s percent range, among the strongest results in obesity research.
How much weight loss does cagrilintide cause?
On its own, cagrilintide produced roughly 10% mean weight loss in phase 2 research, confirming amylin is a real independent lever. Combined with semaglutide as CagriSema, the figure rises into the low-20s percent range in trials. The combination is where its most impressive numbers come from.
Is cagrilintide approved?
It is investigational. Neither cagrilintide alone nor CagriSema is a long-established approved product; the data comes from clinical trials rather than years of real-world use. The results are strong, but the long-term safety and effectiveness picture is still being completed.
Is cagrilintide a GLP-1 drug?
No, and that is the point. Cagrilintide is an amylin analog, not a GLP-1 agonist. It is often discussed alongside GLP-1 drugs because it is combined with semaglutide, but mechanistically it belongs to a different class that works through the amylin pathway.
What is amylin?
Amylin is a hormone released from the pancreas along with insulin after eating. It promotes satiety, slows how fast the stomach empties, and helps regulate blood sugar and food intake. Cagrilintide mimics this hormone, which is why it reduces appetite through a route separate from the GLP-1 drugs.
Related reading
- CagriSema vs retatrutide
- CagriSema vs tirzepatide
- GLP-1 weight-loss drugs guide
- Retatrutide vs semaglutide
References
- Lau DCW, et al. Once-weekly cagrilintide for weight management (phase 2). The Lancet, 2021.
- CagriSema REDEFINE trial program (cagrilintide plus semaglutide), Novo Nordisk.
- Background on amylin and pramlintide pharmacology in metabolic regulation.
This product is sold strictly for laboratory and research use only. It is not approved for human or veterinary use, is not a drug or dietary supplement, and nothing in this article is medical advice, a treatment protocol, or dosing guidance. Always consult the current scientific literature and comply with local regulations.